In fat cells, TZDs turn on a small set of genes, which aren't normally turned on, by targeting the receptor PPARã. To tease out how the medications work specifically, the investigators set out to determine the difference between the genes that are ordinarily turned on in fat cells and the genes that are turned on only when diabetics are given the TZDs.
A new study from the laboratory of Mitchell Lazar, MD, PhD, Director of the Institute for Diabetes, Obesity, and Metabolism at Penn, has found that PPARã can turn genes both on and off. "What regulates it, in this case, is the drug, which is acting as a switch to turn genes on," says Lazar. "This paper shows that we can separate the two different aspects of the drug's action on fat cells." These findings appear in the January 28th online edition of Genes & Development and will appear in the February 15th print issue.
Knowing how to turn a gene off may permit researchers to develop drugs that would decrease TZD-related side effects such as weight gain and edema. Indeed, preclinical research is already underway to design drugs called SPPARMs, selective PPARã modulators, which would specifically target genes in fat cells that can turn off the molecular pathways that may lead to these serious side effects.
Working with mouse fat cells, Lazar's study suggests that one way to get gene-selective actions would be to target this ability to turn off genes without affecting the ability to turn others on. "Since these are separate processes, one through one type of molecular action and one through another, our work shows that this is feasible," says Lazar
How would a SPPARM work? TZDs turn genes on and off by working with molecules called coactivators and corepressors. In addition to its beneficial role, TZDs turn fibroblasts into fat cells by enlisting more coactivators than normal, thus leading to weight gain. The goal is to design a SPPARM that will reduce interaction with corepressors, but increase interaction with coactivators, to separate anti-diabetic effects and weight gain.
"We should be optimistic about finding a new type of drug with the same fat-cell target as TZDs, but which is a selective regulator of gene expression in such a way that will increase the benefit-to-risk ratio of the diabetes treatment," says Lazar.
This research was funded in part by the National Institutes of Health and an unrestricted Bristol Myers Squibb Freedom to Discover Award in Metabolic Research. Other Penn investigators contributing to this research are: Hong-Ping Guan, Takahiro Ishizuka, and Patricia C. Chui, and Michael Lehrke. The authors report no conflicting financial interests.
This release can also be found at: www.uphs.upenn.edu/news.
PENN Medicine is a $2.7 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System (created in 1993 as the nation's first integrated academic health system).
Penn's School of Medicine is ranked #3 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.
The University of Pennsylvania Health System includes three owned hospitals [Hospital of the University of Pennsylvania, which is consistently ranked one of the nation's few "Honor Roll" hospitals by U.S. News & World Report; Pennsylvania Hospital, the nation's first hospital; and Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice
Journal
Genes & Development